Given the high prevalence of cirrhosis, the abovementioned studies suggest that ammonia-lowering approaches, NF-κB inhibitors, myostatin inhibitors, and anaplerotic substrates against mitochondrial dysfunction are potential therapeutics to counteract sarcopenia in chronic liver diseases. Here, MSTN is linked to Cirrhosis.